{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T12:29:20Z","timestamp":1790944160869,"version":"4.1.0"},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,2,19]],"date-time":"2013-02-19T00:00:00Z","timestamp":1361232000000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Clinical Apheresis"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:p>Transplantation is the treatment of choice for end stage renal disease. Kidney transplants convey both a significant survival advantage to the individual recipient as well as cost savings to the medical system. Circulating alloantibodies directed against donor human leukocyte antigens and blood group antigens are fairly common among potential recipients. They are known to injure allografts, shorten allograft survival, and limit access to kidney transplantation. Hence, screening for pretransplant alloantibodies using complement dependent cytotoxic cross\u2010matching and more sensitive techniques such as the solid phase assays, have become routine in an attempt to avoid incompatible donor\u2013recipient pairs and risk stratify those with donor specific antibodies (DSA). By removing harmful antibodies, therapeutic apheresis (TA) has become a critical tool for improving access to transplantation in cases where the immunologic risk had previously been considered unacceptable. It has also allowed us to transplant across the barrier of ABO blood group incompatibility and expand the pool of donors with reasonable success. Furthermore, it is an important tool in the treatment of antibody\u2010mediated rejection. Advanced apheresis technologies, such as immunoadsorption, and the use of TA in combination with innovative paired\u2010donor exchange programs, offer the potential to further improve access and outcomes, minimizing the short comings of one single form of therapy alone. J. Clin. Apheresis 28:56\u201363, 2013. \u00a9 2013 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/jca.21268","type":"journal-article","created":{"date-parts":[[2013,2,19]],"date-time":"2013-02-19T18:22:51Z","timestamp":1361298171000},"page":"56-63","source":"Crossref","is-referenced-by-count":12,"title":["Therapeutic apheresis in kidney transplantation: A review of renal transplant immunobiology and current interventions with apheresis medicine"],"prefix":"10.1002","volume":"28","author":[{"given":"Angie","family":"Nishio-Lucar","sequence":"first","affiliation":[{"name":"Division of Nephrology University of Virginia Health System Charlottesville Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasheed A.","family":"Balogun","sequence":"additional","affiliation":[{"name":"Division of Nephrology University of Virginia Health System Charlottesville Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Sanoff","sequence":"additional","affiliation":[{"name":"Division of Nephrology Duke University School of Medicine Durham North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,2,19]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"US Renal Data System USRDS 2009Annual Data Report. Atlas of chronic kidney disease and end\u2010stage renal disease in the united states national institutes of health national institute of diabetes and digestive and kidney diseases Bethesda MD 2009."},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199912023412303"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/msj.21314"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200007133430207"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01881105"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196809192791201"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196904032801401"},{"key":"e_1_2_6_9_1","volume-title":"Handbook of Kidney Transplantation","author":"Danovitch GM","year":"2001"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200301150-00008"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-012-0635-1"},{"key":"e_1_2_6_12_1","unstructured":"US Renal Data System USRDS 2010Annual Data Report. Atlas of chronic kidney disease and end\u2010stage renal disease in the united states national institutes of health national institute of diabetes and digestive and kidney diseases Bethesda MD 2010."},{"key":"e_1_2_6_13_1","unstructured":"US Renal Data System USRDS 2011Annual Data Report. Atlas of chronic kidney disease and end\u2010stage renal disease in the united states national institutes of health national institute of diabetes and digestive and kidney diseases Bethesda MD 2011."},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03640.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2009101065"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-139X.2011.01032.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1997.tb03744.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)03452-6"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.01178.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2008.02524.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012376"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI103085"},{"key":"e_1_2_6_23_1","first-page":"231","article-title":"Human ABO\u2010incompatible living donor renal homografts","volume":"28","author":"Alexandre GP","year":"1985","journal-title":"Neth J Med"},{"key":"e_1_2_6_24_1","article-title":"ABO\u2010incompatible kidney transplantation","author":"Takahashi K","year":"2012","journal-title":"Transplant Rev [internet]"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00653.x"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000262570.18117.55"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0b013e32834897c1"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.03001.x"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0b013e3283342712"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02591.x"}],"container-title":["Journal of Clinical Apheresis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjca.21268","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jca.21268","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T01:28:28Z","timestamp":1694482108000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jca.21268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1002\/jca.21268"],"URL":"https:\/\/doi.org\/10.1002\/jca.21268","archive":["Portico"],"relation":{},"ISSN":["0733-2459","1098-1101"],"issn-type":[{"value":"0733-2459","type":"print"},{"value":"1098-1101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}